Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Total RNA-seq in the A549 cell line after glucocorticoid re-induction

ABSTRACT: Total RNA-seq in the A549 cell line after glucocorticoid re-induction

PROVIDER: PRJEB42047 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Circularized chromosome conformation capture (4C-seq) in A549 cells after glucocorticoid re-induction

Project description:Circularized chromosome conformation capture (4C-seq) in A549 cells after glucocorticoid re-induction

| PRJEB42000 | ENA

Total RNA-seq in the A549 cell line after glucocorticoid re-induction

Project description:We performed total RNA-seq in the A549 cell line. Cells were treated with either 100 nM dexamethasone or 0.1% ethanol. After 4 hours, cells were washed 2x with PBS and cultured in hormone-free medium for 24 hours, after which cells were treated again for 4 hours with either 100 nM dexamethasone or 0.1% ethanol.

2021-05-03 | E-MTAB-9923 | biostudies-arrayexpress

Studying changes in chromatin accessibility in A549 cells by ATAC-seq after glucocorticoid re-induction

Project description:Studying changes in chromatin accessibility in A549 cells by ATAC-seq after glucocorticoid re-induction

| PRJEB41975 | ENA

Circularized chromosome conformation capture (4C-seq) in A549 cells after glucocorticoid re-induction

Project description:We performed 4C-seq in the A549 cell line to investigate changes in chromatin interactions at the ZBTB16 locus. Cells were treated with either 100 nM dexamethasone or 0.1% ethanol. After 4 hours, cells were washed 2x with PBS and cultured in hormone-free medium for 24 hours, after which cells were treated again for 4 hours with either 100 nM dexamethasone or 0.1% ethanol. Experiments were performed in two biological replicates. For each treatment, 4C-seq data were generated for the following two viewpoints: ZBTB16 promoter-proximal viewpoint coordinates: chr11:113929670-113930464 (hg19) ZBTB16 intronic viewpoint coordinates: chr11:114051224-114051804 (hg19)

2021-05-03 | E-MTAB-9915 | biostudies-arrayexpress

Studying changes in chromatin accessibility in A549 cells by ATAC-seq after glucocorticoid re-induction

Project description:We performed ATAC-seq in the A549 cell line. Cells were treated with either 100 nM dexamethasone or 0.1% ethanol. After 4 hours, cells were washed 2x with PBS and cultured in hormone-free medium for 24 hours, after which cells were treated again for 4 hours with either 100 nM dexamethasone or 0.1% ethanol.

2021-05-03 | E-MTAB-9912 | biostudies-arrayexpress

Genome-wide profiling of Glucocorticoid receptor binding in A549, Nalm-6, MEF WT and MEF GCN5/PCAF double knockout (ChIP-seq)

Project description:To identify the sequences responsible for recruitment of Glucocorticoid receptor (GR) to individual loci, we performed ChIP-seq in four cell lines : A549 (ATTC:CCL-185), Nalm-6 (ATCC:CRL-1567), immortalized mouse embryonic fibroblasts (MEFs)(PMID 21131905), and immortalized PCAF-/-; GCN5flox/ MEFs (PMID 21131905) upon glucocorticoid treatment (1.5 hrs, 1M dexamethasone).

2016-11-10 | E-MTAB-5113 | biostudies-arrayexpress

Total proteome analysis of A549 IFNR knockout and HepG2 cells

Project description:Total proteome analysis of A549 IFNR knockout and HepG2 cells

2023-08-08 | PXD031406 | Pride

Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer

Project description:This is a phase II, randomized, multi-center, open-label, parallel-group study to evaluate the progression-free survival during maintenance therapy. Eligible patients will be treated within a 12-week induction therapy. Those patients achieving CR/PR or SD at 12 weeks and qualifying for maintenance treatment and re-induction treatment with all potential drug components, will be randomized in a ratio of 1:1 to receive chemotherapy plus panitumumab or chemotherapy alone during maintenance. In case of progression, re-induction treatment will be started.

| 2155383 | ecrin-mdr-crc

Glucocorticoid Receptor (GR) ChIP-seq in A549 and U2OS cells

Project description:Glucocorticoid Receptor (GR) ChIP-seq in A549 and U2OS cells

| PRJNA685997 | ENA

Reversal of glucocorticoid resistance by AKT inhibition in T-ALL

Project description:Glucocorticoid resistance is a major driver of therapeutic failure in T-cell acute lymphoblastic leukemia (T-ALL). Here we used a systems biology approach, based on the reverse engineering of signaling regulatory networks, which identified the AKT1 kinase as a signaling factor driving glucocorticoid resistance in T-ALL. Indeed, activation of AKT1 in T-ALL lymphoblasts impairs glucocorticoid-induced apoptosis. Mechanistically, AKT1 directly phosphorylates the glucocorticoid receptor NR3C1 protein at position S134 and blocks glucocorticoid-induced NR3C1 translocation to the nucleus. Consistently, inhibition of AKT1 with MK-2206 increases the response of T-ALL cells to glucocorticoid therapy both in T-ALL cell lines and in primary patient samples thus effectively reversing glucocorticoid resistance in vitro and in vivo. These results warrant the clinical testing of ATK1 inhibitors and glucocorticoids, in combination, for the treatment of T-ALL. This study includes 228 T-ALL samples of which 117 samples are re-analysis of GSE26713.

2013-05-30 | E-GEOD-32215 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data